景岳生物科技股份有限公司

Sidas Japan Launches 'ReCoLA A PROP Edition', a Next-Generation Recovery Sandal Co-Developed with Fast Fitness Japan's Official Online Store 'A PROP' 出典

What are the features of the ReCoLA A PROP Edition?

It features a unique structure registered as a general medical device, combined with COVEROSS® antibacterial and deodorizing processing for clean and comfortable wear.

Where can I purchase it?

It will be available on the official Fast Fitness Japan online store 'A PROP' starting April 1, 2026, at 11:00 AM.

What are the available sizes?

It is available in four sizes: XS, S, M, and L, with two color options: white and black.

Lu Vit Credit Card New Enrollment Campaign: Get 3,000 Lu Vit Credit Points! 出典

What is the application period for the campaign?

The card application period is from April 1, 2026 (Wednesday) to September 30, 2026 (Wednesday).

When will the 3,000 points be awarded?

Points will be awarded around the end of the month, one month after the end of the card usage period, which is until the end of the month two months after the card enrollment month.

Is the use of family cards also eligible for the campaign?

Yes, the use of family cards associated with the main card is also eligible for the campaign.

【景岳】2026年2月 月次売上高 0.16億NTD（前年同月比 -35.5%） 出典

景岳公司在2026年2月的營收是多少？

景岳公司在2026年2月的營收為新台幣1,641萬3千元，約為0.16億元。

與去年同期相比，景岳公司2026年2月的營收有何變化？

與去年同期相比，景岳公司2026年2月的營收減少了35.5%。

景岳公司的公司代碼是多少？

景岳公司的公司代碼是3164。

景岳公司所屬的產業類別是什麼？

景岳公司所屬的產業類別是生物醫藥產業。

這份營收報告的數據是針對哪一個月份？

這份營收報告的數據是針對2026年2月。

【Genmont】February 2026 Monthly Revenue NT$0.16 Billion (YoY -35.5%) 出典

What was Genmont's total revenue for February 2026?

Genmont's total revenue for February 2026 was NT$0.16 Billion, which is equivalent to 16,413 Thousand NTD.

How did Genmont's revenue in February 2026 compare to the previous year?

Genmont's revenue in February 2026 experienced a year-on-year decrease of 35.5%.

What is the company code for Genmont?

The company code for Genmont is 3164.

In which industry does Genmont operate?

Genmont operates in the Biomedical Industry.

What was the specific revenue figure in Thousand NTD for Genmont in February 2026?

The specific revenue figure for Genmont in February 2026 was 16,413 Thousand NTD.

【景岳生物科技股份有限公司】2025年Q4 EPS 0.66元 出典

景岳生物科技股份有限公司在2025年第四季的每股盈餘是多少？

景岳生物科技股份有限公司在2025年第四季的基本每股盈餘為0.66元。

請問景岳生物科技股份有限公司2025年第四季的營業收入總計是多少？

根據提供的資訊，景岳生物科技股份有限公司在2025年第四季的營業收入總計為4.01億元。

景岳生物科技股份有限公司在2025年第四季的稅後淨利為何？

景岳生物科技股份有限公司在2025年第四季的稅後淨利為0.48億元。

這份財報是關於景岳生物科技股份有限公司的哪個年度及季度資訊？

這份財報是關於景岳生物科技股份有限公司在2025年度的第四季資訊。

景岳生物科技股份有限公司所屬的產業類別為何？

景岳生物科技股份有限公司所屬的產業類別為生技醫療業。

景岳公告本公司申請股票上櫃轉上市時所出具之承諾事項暨其後續執行情形 出典

景岳公司股票初次上市時，向臺灣證券交易所承諾了哪些事項？

景岳公司承諾，若其重要子公司財務報告由其他會計師查核簽證，並據以認列投資損益或編製合併財務報告時，本公司之簽證會計師需對財務報表出具不提及其他會計師查核意見之報告。

景岳公司於115年度第1季，在股票上市承諾事項方面有何執行情況？

截至115年3月31日為止，景岳公司並無其重要子公司財務報告由其他會計師查核簽證，並據以認列投資損益或編製合併財務報告之情事，故無須出具特別報告。

景岳公司股票初次上市的承諾事項，是依據哪項函文規定辦理？

景岳公司股票初次上市的承諾事項，是依據臺灣證券交易所股份有限公司民國九十九年一月八日臺證上字第0990000468號函規定辦理。

本次公告的承諾事項，主要與景岳公司的哪項財務報告相關？

本次公告的承諾事項，主要與景岳公司各重要子公司財務報告由其他會計師查核簽證，並據以認列投資損益或編製合併財務報告時，本公司簽證會計師的報告要求有關。

景岳公司股票上櫃轉上市時，所出具的承諾事項，其後續執行情形是基於哪個時間點的資料？

景岳公司股票上櫃轉上市時，所出具的承諾事項，其後續執行情形是基於截至115年3月31日為止的資料。

Jingyue Announces Commitments Made During IPO Listing and Their Subsequent Execution Status 出典

What is the name of the company that made the announcement regarding its IPO commitments?

The name of the company is Jingyue Biotechnology Co., Ltd., and its relationship is Parent Company.

What is the fact date of this announcement and for which quarter of 2026 is it reporting?

The fact date is 115/04/07, and it reports on commitments and execution status for the first quarter of 2026.

What regulation governs the reporting of these IPO commitments and execution status?

It is governed by the Taiwan Stock Exchange Corporation's letter Tai-Zheng Shang-Zi No. 0990000468 dated January 8, 1999.

What commitment did the company make regarding the audit opinion on subsidiary financial statements?

The company's certifying accountant shall issue a report that does not mention the audit opinion of other accountants on the financial statements.

What is the subsequent execution status of the company's commitment as of March 31, 115?

As of March 31, 115 (3/31/115), the situation mentioned in the commitment has not occurred.

【景岳】上場（柜轉市）時の承諾事項及びその後の履行状況に関する公告 出典

景岳生物科技股份有限公司が上場時に行った承諾事項は何ですか？

景岳生物科技股份有限公司は、各重要子会社の財務報告が他の会計士によって監査され、それに基づいて投資損益を認識または連結財務報告を作成する場合、当社の監査担当会計士は、他の会計士の監査意見に言及しない報告書を作成するという承諾を行いました。

この承諾事項は現在どのように履行されていますか？

2026年度第1四半期末（115/3/31）現在、当社には上記のような事象は発生しておらず、承諾事項は適切に履行されていると確認されました。

この公告の目的は何ですか？

台湾証券取引所股份有限公司の規定に基づき、当社株式の初度上場時に提示した承諾事項及びその履行状況について、株主及び市場関係者に公表するためです。

Jingyue Announces Commitments Made During IPO Listing and Their Subsequent Execution Status 出典

What is the name of the company that made the IPO commitments announcement?

The name of the company that made the announcement is Jingyue Biotechnology Co., Ltd.

What is the fact date of the announcement regarding IPO commitments?

The fact date of the announcement regarding IPO commitments is 115/04/07.

Which regulatory letter is cited as the reason for this occurrence?

The regulatory letter cited is Tai-Zheng Shang-Zi No. 0990000468 dated January 8, 1999.

What is the commitment of the company regarding its significant subsidiaries?

The certifying accountant shall issue a report not mentioning other accountants' opinions if significant subsidiaries are audited by other accountants.

What was the execution status of the IPO commitments as of March 31, 115?

As of March 31, 115, the situation regarding the commitment has not occurred.

【景岳】2026年3月売上高 0.38億（前年同月比 -12.6%） 出典

景岳（3164）の2026年3月の売上高はいくらでしたか？

景岳（3164）の2026年3月の売上高は0.38億台湾ドルでした。

前年同月と比較して、景岳（3164）の2026年3月の売上高はどうでしたか？

前年同月比で-12.6%の減収となりました。